Phase II study of S-1 alternate-day and bevacizumab in elderly patients with advanced colorectal cancer
Phase of Trial: Phase II
Latest Information Update: 15 Oct 2018
At a glance
- Drugs Bevacizumab (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms J-SAVER
- 09 Oct 2018 Status changed from active, no longer recruiting to completed.
- 20 Jan 2018 Primary endpoint (Progression-free survival) has been met, according to results presented at the 2018 Gastrointestinal Cancers Symposium.
- 20 Jan 2018 Results presented at the 2018 Gastrointestinal Cancers Symposium.